Investigating the loco-regional control of simultaneous integrated boost intensity-modulated radiotherapy with different radiation fraction sizes for locally advanced non-small-cell lung cancer: clinical outcomes and the application of an extended LQ/TCP model

Bo Qiu 1,2,3†, Qi Wen Li 1,2,3†, Xin Lei Ai 1,2,3†, Bin Wang 1,2,3, Jian Huan 4, Zheng Fei Zhu 5, Gen Hua Yu 6, Ming Ji 7, Hai Hang Jiang 7, Cheng Li 8, Jun Zhang 1,2,3, Li Chen 1,2,3, Jin Yu Guo 1,2,3, Yin Zhou 7* and Hui Liu 1,2,3*

Abstract

Background: To investigate the loco-regional progression-free survival (LPFS) of intensity-modulated radiotherapy (IMRT) with different fraction sizes for locally advanced non-small-cell lung cancer (LANSCLC), and to apply a new radiobiological model for tumor control probability (TCP).

Methods: One hundred and three LANSCLC patients treated with concurrent radiochemotherapy were retrospectively analyzed. Factors potentially predictive of LPFS were assessed in the univariate and multivariate analysis. Patients were divided into group A (2.0 ≤ fraction size < 2.2 Gy), B (2.2 ≤ fraction size < 2.5 Gy), and C (2.5 ≤ fraction size ≤ 3.1 Gy) according to the tertiles of fraction size. A novel LQRG/TCP model, incorporating four Rs of radiobiology and Gompertzian tumor growth, was developed to predict LPFS and compared with the classical LQ/TCP model.

Results: With a median follow-up of 22.1 months, the median LPFS was 23.8 months. Fraction size was independently prognostic of LPFS. The median LPFS of group A, B and C was 13.8, 35.7 months and not reached, respectively. Using the new LQRG/TCP model, the average absolute and relative fitting errors for LPFS were 6.9 and 19.6% for group A, 5.5 and 8.8% for group B, 6.6 and 9.5% for group C, compared with 9.5 and 29.4% for group A, 16.6 and 36.7% for group B, 24.8 and 39.1% for group C using the conventional LQ/TCP model.

(Continued on next page)
Conclusions: Hypo-fractionated IMRT could be an effective approach for dose intensification in LANSCLC. Compared with conventional LQ model, the LQRG model showed a better performance in predicting follow-up time dependent LPFS.

Keywords: Locally advanced non-small-cell lung cancer, Loco-regional progression-free survival, Fraction size, Hypo-fractionation, Tumor control probability model

Background
Concurrent chemoradiotherapy (CCRT) has long been established as the standard therapy for unresectable locally advanced non-small-cell lung cancer (LANSCLC), while the loco-regional control (LRC) and overall survival (OS) were suboptimal. Patients still experienced a loco-regional progression rate of approximately 30~40% at 3 years in most of the randomized trials [1]. After the impact of radiation dose for NSCLC was established [2], efforts to improve the LRC have been focused on increasing the total irradiation dose. A major finding in RTOG0617 was that total dose escalation of 74Gy with 2Gy per fraction failed to improve LRC or OS [3]. Therefore, hypo-fractionation radiotherapy could be another attempt to achieve better local control for LANSCLC.

Hypo-fractionation radiotherapy enables the delivery of an increased biologically effective dose (BED) without extending the overall treatment time (OTT). Image guided radiotherapy (IGRT) and intensity-modulated radiation therapy (IMRT) conform the radiation dose to the tumor and spare adjacent critical organs [4]. Simultaneous integrated boost (SIB)-IMRT has been developed recently as a dose intensification technique, which delivers different dose prescriptions to different target volumes with promising local control. However, there are limited data on hypo-fractionated SIB-IMRT concurrent with chemotherapy in LANSCLC, and the feasibility and efficacy needs to be investigated.

Other than that, setting up tumor control probability (TCP) model remained crucial for developing new fraction scheme for radiotherapy. The linear-quadratic (LQ) model provides the theoretical background for estimating TCP via the calculation of BED. Nevertheless, the conventional LQ/TCP model was proved to be ineffective in modeling the radio-biological response of hypo- and hyper-fractionated IMRT for lung cancer. We recently developed a novel LQ model incorporating cell repair, redistribution, reoxygenation, regrowth and Gompertzian tumor growth (LQRG/TCP model) to improve the modeling accuracy for the local tumor control of small cell lung cancer (SCLC) [5]. Compared with LQ/TCP model and its following modifications, LQRG which incorporates all the four "R"s of radiobiology, might be more realistic assumptions for the prediction of TCP. It is interesting to explore whether the LQRG/TCP model can as well explain the clinical effect of hypo-fractionated IMRT with different fraction sizes in the case of NSCLC. As to our knowledge, little work has been done to modeling the time dependent loco-regional progression-free survival (LPFS) in the radiation of NSCLC and use it as a theoretical foundation to interpret the fraction size dependent clinical results of the IMRT. Some authors tried to provide more clinically relevant TCP modeling of tumor response to radiotherapy in NSCLC [6–8]. However, they were mainly restricted to stereotactic body radiation therapy (SBRT) and did not incorporate the redistribution and re-oxygenation mechanisms of clonogenic cell and the interplay of radiation treatment between fractions into the LQ formalism.

This study retrospectively analyzed the LPFS of patients with LANSCLC, who were treated by SIB-IMRT concurrent with chemotherapy at different doses per fraction, and provided evidence in support of hypo-fractionated SIB-IMRT as an alternative of conventional fractionation. An recently developed extended LQ model, LQRG, was applied to account for the LPFS of the IMRT for NSCLC.

Methods
Acquisition of clinical data
We retrospectively reviewed the records of 103 LANSCLC patients treated from January 2012 to May 2015 in our Center. Patients included in our study had: 1.pathologically confirmed LANSCLC (stage IIIA/B); 2.treatment with SIB-IMRT and concurrent chemotherapy; 3.ECOG performance status score 0–2 and life expectancy of more than 6 months. Patients who received prior thoracic surgery or thoracic radiation, or had other coexisting malignancy were excluded. The 7th edition of American Joint Committee on Cancer staging system was used to stage the diseases. This study was approved by the ethics committee of our center. Written informed consent to use clinical data was obtained.

Radiotherapy and concurrent chemotherapy
Patients were immobilized and simulated according to the standard protocol of lung cancer in our center [9]. Gross tumor volume (GTV) was defined as visible
primary tumors and involved lymph nodes on CT and/or PET scans. The criteria of lymph node positivity included: short axis size ≥10 mm on pretreatment CT scan, reported positive on the pretreatment PET scan, or biopsy positive on mediastinoscopy or endobronchial ultrasound-guided biopsies. The GTVs were composite volumes from CT scans of all breathing phases. Clinical target volume (CTV) included the primary lung tumor with a 0.6 cm margin, the ipsilateral hilum, involved lymph nodes region and high-risk lymph nodal regions (for example, if 4R was involved, 4 L and 2R were included in CTV) (Supplementary Figure 1). The planning target volume for GTV (PTV1) and CTV (PTV2) covered the GTV and CTV with a 0.5-cm margin, respectively.

SIB-IMRT technique was used to deliver different dose prescriptions to PTV1 and PTV2 in the same treatment fraction (for example, 65 Gy to PTV1 and 50 Gy to PTV2 in 25 fractions). The dose and fractions were decided by planning clinic discussion and limited by normal tissue constraints. The prescription dose to PTV1 was 60–70 Gy, which was the typical radical dose for LANSCLC. The prescription dose to PTV2 was 45-54 Gy, which was a standard prophylactic dose. Dose constraint for organs at risk (OAR) included: the maximum spinal cord dose < 46 Gy, mean lung dose (MLD) < 20 Gy and the lung volumes irradiated above 20 Gy (V20) < 35%, the maximum esophagus dose < 110% of prescription dose, and V40 of the heart < 50%. The actual radiation dose to PTV was defined as the minimum dose received by 95% of PTV. Radiotherapy was delivered using daily cone-beam CT image guidance. The concurrent chemotherapy were platinum-based double-agent regimen.

Follow-up

Patients were followed up 2 months after CCRT, then every 3 months for the first 3 years and every 6 months thereafter. Routine surveillance imaging included chest, abdomen CT and brain MRI. Patients underwent bone scan when suspected for bone metastasis, and PET scan when suspected for systemic progression. Loco-regional progression, distant metastasis and survival status were recorded. LPFS was calculated from the last date of CCRT and/or loco-regional progression to the date of last visit before November 30th, 2018. Infield failure was defined as recurrent tumors mapped within PTV1. Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE 4.0) was used to evaluate the toxicities.

Statistical analyses

Continues variables were presented as median and range. The survival analyses were performed using the Kaplan-Meier method. Clinical and dosimetric factors potentially predictive of LPFS were assessed using Cox proportional hazards modeling. All statistical analyses were performed with SPSS 19.0 software (IBM), and a P value<0.05 was considered statistically significant.

Tumor control probability modeling

The conventional LQ model combined with a Binomial TCP model were described in Supplementary 1. The construction of LQRG model combined with a Gaussian TCP model are briefly presented below.

The model name “LQRG” stands for the Linear Quadratic model with 4R effects and Gompertzian tumor growth. It takes account of the four “R”s effects, and add features of delayed regrowth [10] and Gompertzian tumor growth [11].

The surviving fraction (SF) of clonogenic cells is expressed as:

\[
SF(t) = \exp\left(-\alpha D - \beta G(\tau_s)D^2 + \frac{1}{2\sigma^2} G(\tau_s)D^2 + \ln 2 \frac{T - T_k}{\tau_R} + \left( \ln 2 \frac{L}{\tau_D} \right)^2 \right)
\]

where \( G(\tau) \) is the generalized Lea-Catcheside function [11, 12], defined by Eq. 6; \( \tau_R \) is the average DNA repair time; \( \tau_s \) is average resensitization time; \( \sigma \) is the variance of the Gaussian distribution of random variable \( \alpha \), immediately after an acute irradiation; \( T \) is the treatment time; \( T_k \) is the delayed time for regrowth; \( t \) is the elapsed time since the end of treatment. The first and second terms describe cell killing by one-track and two-track action (and possible repair), respectively. The third term refers to intercellular diversity of radiosensitivity and resensitization [13]. The forth term refers to the delayed tumor regrowth, while the last term involving parameter \( \delta \) refers to the Gompertzian tumor growth after radiation [14]. Although quite different phenomena, redistribution and reoxygenation do share a common outcome [15], a postirradiation increase in the sensitivity of cells that survive an initial or partial exposure. Following Brenner et al. [13], we denote this common outcome resensitization and incorporates these two “R”s in the third term of the exponent of SF.

\[
G(\tau) = \left( \frac{2}{D^2} \right)^{1/2} \int_0^T R(u) du \int_0^u R(w) \exp\left(-\frac{u-w}{\tau_R}\right) dw
\]

The TCP is:

\[
TCP(t) = 1 - \frac{1}{\sqrt{2\pi}} \int_{-\infty}^{\infty} \exp\left(-\frac{x^2}{2}\right) dx
\]
\[ x_0 = \frac{\mathcal{K} - K_{cr}}{\sigma_k} = \frac{SF - K_{cr}}{\sigma_k} / K_0 \]  

(4)

where \( \sigma_k \) is the Gaussian width for the distribution of tumor cell numbers [7]. \( K_0 \) is the initial average number of clonogenic cells and \( K_{cr} \) is a critical number under which the tumor would be controlled for an individual patient [7].

BED for the LQRG model is then expressed as:

\[ BED = \left( D + \beta G(t_k) \right) \mathcal{K} - K_{cr} \frac{1}{\sigma_k} \ln(2) (T - T_k) \]  

(5)

To compare the \( \alpha/\beta \) ratio at the same sense of the conventional LQ model, an effective \( \beta_e \), \( \beta_{eff}, \) was defined for the LQRG model.

\[ \beta_{eff} = n \beta G(t_p) \frac{H}{\sigma_k^2} G(t_p) \]  

(6)

where \( n \) was the number of fractions. With this definition of \( \beta_{eff} \), the quadratic term of \( D^2 \) in SF of Eq. 5 can be cast into the same form as in Eq. 2: \( -\beta_{eff} D^2 \). This parameter will be utilized in later comparison of \( \alpha/\beta \) between the conventional LQ model and new LQRG model in a fair way.

The relations between generalized Lea-Catcheside function \( G(t) \) and the recovery time constant \( r \) were computed using numerical integration method. Dose and volume of GTV were extracted from the dose-volume histograms (DVHs) of radiation plans. The clinical endpoint linked to the TCP for model fitting was the time dependent LPFS. The calculated TCP(t) is fitted to the measured LPFS(t), where \( t \) is the time from the end of radiotherapy to the time of follow up. The least chi-square method was utilized in the fitting [16]. The free parameters in the function were determined by minimizing the cost function, which was the mean absolute error, using a gradient descent method. The absolute and relative fitting errors for LPFS was calculated using formulas in Additional file 1: Appendix A of our previous study [5]. The confidence intervals for estimated parameters were determined following standard procedures in nonlinear regression [17]. The maximum log likelihood and Akaike information criterion (AIC) was computed to compare the fitting goodness and synthetic quality of the models (see Additional file 1: Appendix B of our previous study [5]). In accordance with Additional file 1: Appendix A and B of [5], the minimization of the chi-square cost function, the mean absolute error (MAE), is equivalent to the maximization of log likelihood. Leave-one-out cross validation based on the time-dependent LPFS samples was performed to compare the generalization capabilities of the models. All the aforementioned calculations in tumor control probability modeling were conducted on a cloud-based clinical data service platform OncoEvidance v1.0 (Homology Medical, Suzhou, China, 2019) and the fitted model of LQRG was embedded in the radiobiology module of Zeus Cloud TPS (Treatment Planning System) v1.0 (Homology Medical, Suzhou, China, 2019).

**Results**

**Patient characteristics**

The median actual radiation dose to PTV1 was 63.8Gy (55.6 ~ 69.3) with a median fraction size of 2.4Gy (2.0 ~ 3.1). Patients were divided, according to tertiles of fraction size, into group A (2.0 \( \leq \) fraction size < 2.2Gy, \( n = 34 \)), group B (2.2 \( \leq \) fraction size < 2.5Gy, \( n = 34 \)) and group C (2.5 \( \leq \) fraction size \( \leq \) 3.1Gy, \( n = 35 \)). Patient demographics and disease characteristics for three groups are listed in Table 1. The radiation dosimetry data are listed in Supplementary Table 1. The relative dose intensity of concurrent chemotherapy is listed in Supplementary Table 2.

**Loco-regional control and survival**

With a median follow-up of 22.1 months (range, 5.4 ~ 64.3), the median OS was not reached. The 2-year and 5-year OS rates were 66.1 and 23.1% respectively.

The median LPFS was 23.8 months. LPFS rates dropped from 100% at time 0 to 73.9% at 1 year, 48.6% at 2 years, and 44.7% at 3 years. A total of 47 patients developed loco-regional progression.

We assessed the impact of the following variables on LPFS: age, sex, ECOG PS, histology, clinical stage, concurrent chemotherapy, as well as GTV volumes, showed similar distribution among three groups.

**Patterns of failure**

Seventy-five patients (72.8%) had progression of disease: 25 (24.3%) had local loco-regional progression alone, 28 (27.1%) had distant progression alone, and 22 (21.4%)
had both loco-regional and distant progression. The loco-regional progression sites included ipsilateral lung (n = 32), mediastinum/supraclavicular lymph nodes (n = 6) and both (n = 9). There were a total of 42 (40.8%) in-field loco-regional failures and 5 (4.9%) out-field loco-regional failures.

Toxicities
Radiation pneumonitis and esophagitis were the most common acute toxicities. Grade ≥ 3 pneumonitis and esophagitis were observed in 6 (5.7%) and 18 (17.1%) patients, respectively. There was no statistical difference in the incidence of complications among three groups. Life-threatening hemoptysis was observed in one patient irradiated at 63Gy in 21 fractions (3.0Gy per fraction) 2 months after RT. More information on toxicities are provided in Supplementary Table 3.

Modeling
The mean total GTV doses were 62.92Gy, 64.07Gy and 62.89Gy for groups A, B and C, respectively. The mean GTV volumes were 105.83, 102.21 and 108.51cm³, respectively.

Table 1 Characteristics of patients (n = 103)

| Characteristics                              | All patients | Group A (n = 34) | Group B (n = 34) | Group C (n = 35) | p value |
|----------------------------------------------|--------------|------------------|------------------|------------------|---------|
| Sex                                          |              |                  |                  |                  |         |
| Male                                         | 88 (85.4)    | 30 (88.2)        | 29 (85.3)        | 29 (82.9)        | 0.818   |
| Female                                       | 15 (14.6)    | 4 (11.8)         | 5 (14.7)         | 6 (17.1)         |         |
| Age (year)                                   |              |                  |                  |                  | 0.084   |
| Median                                       | 58           | 61               | 58               | 53               |         |
| Range                                        | 30 ~ 79      | 38 ~ 79          | 34 ~ 77          | 30 ~ 72          |         |
| ECOG PS                                      |              |                  |                  |                  | 0.569   |
| 0–1                                         | 87 (84.5)    | 27 (79.4)        | 29 (85.3)        | 31 (88.6)        |         |
| 2                                           | 16 (15.5)    | 7 (20.6)         | 5 (14.7)         | 4 (11.4)         |         |
| Histology                                    |              |                  |                  |                  | 0.315   |
| Squamous cell carcinoma                      | 54 (52.4)    | 22 (64.7)        | 18 (52.9)        | 14 (40.0)        |         |
| Adenocarcinoma                               | 45 (43.7)    | 10 (29.4)        | 15 (44.1)        | 20 (57.1)        |         |
| Adeno-squamous cell carcinoma                | 2 (1.9)      | 1 (2.9)          | 0 (0)            | 1 (2.9)          |         |
| Lymphoepithelioma like carcinoma             | 2 (1.9)      | 1 (2.9)          | 1 (2.9)          | 0 (0)            |         |
| Clinical stage (7th edition)                 |              |                  |                  |                  | 0.229   |
| IIIA                                         | 39 (37.9)    | 9 (26.5)         | 14 (41.2)        | 16 (45.7)        |         |
| IIIB                                         | 64 (62.1)    | 25 (73.5)        | 20 (58.8)        | 19 (54.3)        |         |
| Actual radiation dose (Gy)                   |              |                  |                  |                  | 0.259   |
| Median                                       | 63.8         | 63.5             | 63.9             | 64.0             |         |
| Range                                        | 55.6 ~ 69.3  | 57.2 ~ 65.9      | 59.5 ~ 69.3      | 55.6 ~ 68.2      |         |
| Radiation fraction size (Gy)                 |              |                  |                  |                  | < 0.001 |
| Median                                       | 2.4          | 2.1              | 2.4              | 2.8              |         |
| Range                                        | 2.0 ~ 3.1    | 2.0 ~ 2.2        | 2.2 ~ 2.5        | 2.5 ~ 3.1        |         |
| Overall treatment time (weeks)               |              |                  |                  |                  | < 0.001 |
| Median                                       | 5.3          | 6.0              | 5.3              | 4.6              |         |
| Range                                        | 3.7 ~ 7.9    | 5.4 ~ 7.9        | 4.7 ~ 7.5        | 3.7 ~ 6.0        |         |
| Concurrent chemotherapy                      |              |                  |                  |                  | 0.170   |
| cisplatin + Paclitaxel/Docetaxel             | 73 (70.9)    | 20 (58.8)        | 25 (73.5)        | 28 (80.0)        |         |
| cisplatin + Pemetrexed                       | 14 (13.6)    | 4 (11.8)         | 6 (17.6)         | 4 (11.4)         |         |
| cisplatin + Etoposide                        | 2 (1.9)      | 1 (2.9)          | 1 (2.9)          | 0                |         |
| Others                                       | 14 (13.6)    | 9 (26.5)         | 2 (5.9)          | 3 (8.6)          |         |

Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, BED Biological effective dose. Categories were compared using Chi-square test. Medians were compared using non-parametric test.
Figure 1 presents the results of TCP (or LPFS) model fitting within a duration of 70 months. Compared with the excellent fit of the LQRG model, fitting of the LQ model failed immediately after 20 months. Using the new LQRG/TCP model, the average absolute and relative fitting errors for LPFS were 6.9 and 19.6% for group A, 5.5 and 8.8% for group B, 6.6 and 9.5% for group C, compared with the average absolute and relative fitting errors for LPFS as 9.5 and 29.4% for group A, 16.6 and 36.7% for group B, 24.8 and 39.1% for group C using the conventional LQ/TCP model. The values of model parameters and their confidence intervals are detailed in Table 3. Supplementary Table 4 lists the fitting errors of LQ model and LQRG model for the relation between LPFS and follow-up time after treatment. Figure 2 shows the BED-LPFS relation predicted at the 13th and 48th month, and suggests a better agreement between data and prediction in the LQRG model.

Supplementary Table 5 lists the intermediate results of the calculation of LPFS at the end of the treatment.

### Table 2 Univariate analysis of prognostic factors of loco-regional control (n = 103)

| Variable                                      | Univariate analysis | HR, 95% CI          |
|-----------------------------------------------|---------------------|---------------------|
| Sex (male vs. female)                         | 0.490               | 0.722 (0.286 ~ 1.821) |
| Age (≥58 vs. < 58 yrs)                        | 0.571               | 0.850 (0.485 ~ 1.491) |
| ECOG PS (2 vs. 0 ~ 1)                         | 0.702               | 0.862 (0.404 ~ 1.842) |
| Histology (non-squamous vs. squamous)         | 0.099               | 1.617 (0.913 ~ 2.864) |
| cTNM stage (IIIA vs. IIIB)                    | 0.703               | 0.893 (0.499 ~ 1.598) |
| GTV volume (≥785 vs. < 785 cm³)               | 0.475               | 1.227 (0.700 ~ 2.152) |
| Actual radiation dose (≥63.8 vs. < 63.8Gy)    | 0.575               | 1.175 (0.669 ~ 2.063) |
| Traditional BED (≥78.9 vs. < 78.9Gy)         | 0.134               | 0.648 (0.367 ~ 1.142) |
| Radiation fraction size                       | **0.003**           |                     |
| (2.0 ~ 2.2 vs. 2.5 ~ 3.5Gy)                  | 0.002               | 3.609 (1.572 ~ 8.286) |
| (2.2 ~ 2.5 vs. 2.5 ~ 3.5Gy)                  | 0.264               | 1.591 (0.704 ~ 3.596) |
| OTT (≥5.3 weeks vs. < 5.3 weeks)              | **0.008**           | 2.246 (1.236 ~ 4.082) |
| Concurrent chemotherapy                       | 0.326               |                     |
| (AP vs. TP /DP)                               | 0.176               | 0.522 (0.204 ~ 1.337) |
| (EP vs. TP /DP)                               | 0.562               | 1.809 (0.244 ~ 13.389) |
| (Others vs. TP /DP)                           | 0.361               | 1.432 (0.663 ~ 3.091) |

**Abbreviations:** ECOG PS Eastern Cooperative Oncology Group performance status, BED Biological effective dose, ORT Overall radiation time, TP Nedaplatin or cisplatin + Paclitaxel, DP Nedaplatin or cisplatin + Docetaxel, AP Nedaplatin or cisplatin + Pemetrexed, TKI EGFR tyrosine kinase inhibitor, HR hazard ratio, CI Confidence interval

Fig. 1 Model fitting to LPFS data using (a) the classical LQ and TCP models, or (b) the new LQRG and TCP
These intermediate items were extracted from the exponent part of the SF from both models. Supplementary Figure 2 shows the relation between generalized Lea-Catcheside function $G(\tau)$ and the recovery time constant $\tau$ for both schemes. Table 4 presents the metrics characterizing the quality of the LQ and LQRG models.

**Discussion**

The standard radiation scheme for LANSCLC consists of a total dose of 60~70Gy delivered in a fraction size of 2Gy per day. Various treatment schemes have been tried in an effort to improve local control by either dose escalation or shortening the total treatment time through unconventional fractionation [18]. The results from RTOG 0617 suggested that the balance between treatment-related toxicities and dose escalation must be taken into account seriously [3]. Asian patients physically have smaller lungs volume than western patients, which make it hard to escalate the total dose beyond 70Gy. Therefore, we tried to use SIB-IMRT technique to escalate the fraction size. Our results showed that in the range of 60~70Gy, total radiation dose was not

| Table 3 Model Parameter Values |
|-------------------------------|
| Parameter | LQ | LQRG |
|-----------|----|------|
| $\rho$ (cm$^{-3}$) | $7.965 \times 10^9$ | $2.296 \times 10^9$ [1.23 $\times 10^9$, 4.19 $\times 10^9$] |
| $\sigma$ (Gy$^{-1}$) | 0.3932 | 0.06691 [0.0656, 0.0721] |
| $\beta$ (Gy$^{-2}$) | 0.0429 | 0.1039 [0.0071, 0.1996] |
| $\sigma^2$ (Gy$^{-2}$) | / | 0.1939 [0.0893, 0.2014] |
| $\tau_R$ (hour) | / | 6.32 [5.5, 6.73] |
| $\tau_S$ (hour) | / | 3.04 [1.12, 4.99] |
| $\tau_P$ (day) | 113.8 | 84.55 [30.1, 176.27] |
| $T_k$ (hour) | 246.06 | 533.5 [0.024, 1979.5] |
| $K_c$ | / | $2.367 \times 10^3$ [2.1 $\times 10^3$, 3.12 $\times 10^3$] |
| $\sigma_k$ | / | $1.03 \times 10^6$ [7.75 $\times 10^5$, 1.2 $\times 10^6$] |
| $\delta$ | / | 0.2645 [0.2368, 0.2817] |
| $\alpha/\beta$ in LQ and $\alpha/\beta_{eff}$ in LQRG (Gy)$^*$ | 9.2 | 10.06 / |

LQ Linear-quadratic model, LQRG LQ model incorporating cell repair, redistribution, reoxygenation, regrowth and Gompertzian tumor growth

Fig. 2 Model fitting to the LPFS data versus BED. The classical LQ and TCP models fitting to LPFS data at (a) 13th month and at (c) 48th month. The new LQRG and TCP model fitting to LPFS data at (b) 13th month and at (d) 48th month.
prognostic of LPFS. LPFS was improved by the escalation of radiation fraction size (HR, 0.590; CI, 0.348–1.001). It implied that hypofractionated SIB-IMRT could be an alternative of conventional fractionation.

Data on the efficacy of hypo-fractionated radiotherapy for LANSCLC remain limited. A systematic review of the literature about radical-intent hypo-fractionated RT for LANSCLC included 33 studies [19]. The RT dose ranged from 45.0 to 85.5 Gy, and was delivered at 15–35 fractions at a dose per fraction ranging from 2.3 to 3.5Gy. OS was found to be associated with tumor BED. A phase II study showed that escalating radiation dose to the FDG-avid tumor detected by midtreatment PET provided a favorable LRC in stage II or III NSCLC [20]. RT was delivered in 30 daily fractions up to a total physical dose of 86Gy. It achieved a promising 2-year infield LRC rate of 82% and overall LRC rate of 62%. Our study compared the LRC of different radiation fraction size and showed that hypo-fractionation (over 2.5Gy per fraction) achieved a longer LRC time than conventional fractionation. The possible advantage of hypo-fractionation includes the escalation of BED and shortening of treatment time, which is believed to limit tumor repopulation [21]. A work by Machtay et al. examined the relationship between BED and treatment outcome in conventionally fractionated and hyper-fractionated regimens, where a 1Gy increase in BED resulted in a 3% improvement in LPFS [22]. It has been reported that there is a loss of absolute 3-year survival rate of 1.6% per day OTT prolongation beyond 6 weeks [23]. Consistent with these previous findings, our data showed that fraction size and OTT were associated significantly with LPFS, and fraction size turned out to be an independent prognostic factor.

Calculated by the classical LQ model, the order of the BEDs of all three patient groups correctly predicted the height order of the LPFS curves, but the overall fitting of LPFS for NSCLC patients from follow-up data failed again just as in the case of SCLC, thereby reaffirming its incapability of TCP prediction. The LQRG and the new TCP model, however, succeeded in fitting and predicting the follow-up time dependent LPFS, which, as pointed out in the case of SCLC [5], contributed mainly to two model improvements: namely, one accounting for the 4R effect of radiobiology and the other for more reasonable assumptions for the clonogenic regrowth and cell number distribution.

As in the work on SCLC [5], an additional analysis of the intermediate results of the SF and BED further confirmed the previously revealed mechanisms behind the LQRG models, namely the positive difference between the three schemes made by the resensitization term, the slowing down of the rapid decaying rate of the LPFS as time proceeded on by the Gompertzian term and the reformation of TCP with $K_r$, and the characteristic distinctions between the three schemes caused by the gaps among the three curves of Lea-Catchside function. Once again, these distinctions from Lea-Catchside function were embodied in the second and third term of the SF in (Eq. 5) and subtly balanced by other factors to contribute to the final comparative clinical results. For example, with the optimized value of the $\tau_R = 6.32$ h, G (\(\tau_R\)) in LQRG model were 0.036, 0.040 and 0.049 for groups A, B and C, respectively, which were larger than those corresponding values of 0.033, 0.037 and 0.045 in conventional LQ model. This implied the stronger cell killing effect by two-track actions in LQRG model which might have more accurately represented the interplay between dose fractions through its precise numerical calculation of Lea-Catchside function. Moreover, the models from both conventional LQ and LQRG revealed the subtle effect of the duration of treatment through the term representing the delayed regrowth of the tumor $ln2(T-T_k)/\tau_P$, which slightly favored short treatment duration with larger fraction size in hypo-fractionated IMRT as had been anticipated in clinical settings. Consequently, the BED of the LQRG model for groups A, B and C were 85.93Gy, 91.03Gy and 95.35Gy respectively, which was in good agreement with the clinical observation that the 2.5–3.1Gy per fraction concurrent with chemotherapy showed the best LPFS. Compared with the BED of the conventional LQ model, the relative difference between the BEDs was amplified in LQRG model, which might better explain the additional long-term benefit for schemes with larger fraction sizes.

A close examination of the optimized model parameters revealed that they fell well into the published data range. The $\alpha$ was 0.067, close to the value for NSCLC in

| Table 4 Model Quality Metrics |
|------------------------------|
| Number of samples           | LQ          | LQRG         |
|------------------------------|-------------|--------------|
| Number of parameters         | 5           | 11           |
| Maximum log likelihood       | 1.07        | 117,14       |
| Akaike Information Criterion | 7.86        | −212.27      |
| Average prediction accuracy in leave-one-out cross validation (%) | 64.7%       | 88.2%        |

LQ Linear-quadratic model, LQRG LQ model incorporating cell repair, redistribution, reoxygenation, regrowth and Gompertzian tumor growth
previous study [7]. To comparatively evaluate the value of $\beta$ with published data using conventional LQ model, we recast the Eq. 5 into the form of LQ model by introducing an effective parameter $\beta_{\text{eff}}$ in Eq. 6. Rather than compute the $\alpha/\beta$ ratio as in conventional LQ model, we computed the $\alpha/\beta_{\text{eff}}$ ratio in LQRG model to compare with its conventional counterpart, $\alpha/\beta$. The optimized value of $\alpha/\beta_{\text{eff}}$ ratio in LQRG model was 10.06, which agreed well with the published consensus of around 10 for NSCLC [24]. The cell number doubling time $T_D$ was 84.55 days, closed to the clinically agreed value of nearly 3 months for NSCLC [7, 25]. The delay regrowth time $T_K$ is 533.5 h or 22.2 days, close to the clinically agreed value of nearly 1 months [7, 25]. The repair and resensitization time constants were 6.32 h and 3.04 h respectively, within the range of fitted laboratory-based experimental data from 1 h to tens of hours [13].

The preferred log likelihood of LQRG model was 117.14, which was slightly higher than that of LQG (100.52) and substantially higher than that of LQ (1.7), indicating the reasonable improvements of the fitting capability of LQRG model over those of LQG and LQ. In order to evaluate the risk of overfitting for LQRG model with six more variables than that of conventional LQ and TCP model, AIC was developed for all the three models. AIC, which acts as an operational way of trading off the complexity of an estimated model against how well the model fits the data, is a measure of the fitting quality of an estimated statistical model, with lower value indicating higher model quality. AIC not only rewards goodness of fit, but also penalizes the number of estimated parameters which is closely related to overfitting. The fact that AIC of the fitting of LQRG model to the data was $-212.27$, slightly lower than that of LQG model ($-183.03$) and substantially lower than that of LQ model ($7.86$) validated LQRG’s superior synthetic model quality with reasonably low overfitting risk. In addition, leave-one-out cross validation for the three models showed 88.2% average prediction accuracy for LQRG model, with 85.6% for LQG and 64.7% for LQ respectively. This result of leave-one-out cross validation again demonstrated LQRG’s sound predictive power and a better generalization capability with acceptable overfitting risk. Compared to conventional LQ and TCP model, although six additional variables were added to the new models, the mechanistically driven nature of these variables could potentially interpret the outstanding balance between fitting accuracy and generalization capability. As to our knowledge, this is the first theoretical work to accurately predict the follow-up time dependence of LPFS for NSCLC with hypo-fractionated SIB-IMRT. Since the proposition of LQRG model in SCLC [5], this work has applied the same LQRG modelling framework in a different type of lung cancer -- NSCLC, and confirmed its universality in follow-up time dependent LPFS modelling for lung cancer. In this study, death was not considered as an event in the LPFS estimation if the patient was not dead of loco-regional progression. Distant metastasis was the main pattern of failure that affected survival in locally advanced NSCLC [26]. Our data showed 50 patients (48.5%) developed distant metastasis during follow-up. Therefore, considering death as an event in the LPFS might overestimate the loco-regional failure and affect the following model fitting.

This study was limited by its retrospective nature. The dose and fractions were decided by planning clinic discussion and limited by normal tissue constraints. The prescription might have been influenced by doctor’s preference, tumor volume, performance status and pulmonary function. Some factors, such as tumor volume and PS, might influence the local control. Therefore, we included these potential confounding factors in univariate and multivariate analysis to minimize the confounding effect. This study was also limited by the lack of prospective collection of toxicity data. There might be an underestimation of toxicity. Therefore, dose escalation through hypo-fractionated SIB-IMRT should always be performed with caution of toxicity. This study was also limited by a modest sample size and events which might cause overfitting of the model. A larger sample size with a longer follow-up time is warranted.

Conclusions
Our study shows improved loco-regional control in patients treated with an escalated fraction size in the setting of concurrent chemotherapy. It supported that, for Asian patients, hypo-fractionated SIB-IMRT could be a feasible and effective approach for dose intensification in LANSCLC. Compared with conventional LQ model, the LQRG model showed a better performance in follow-up time dependent LPFS modelling. A larger sample size and longer follow-up time was warranted before widely applying hypo-fractionated RT to LANSCLC in clinical practice.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13014-020-01555-x.

Additional file 1.

Abbreviations
LPFS: Loco-regional progression-free survival; IMRT: Intensity-modulated radiotherapy; LANSCLC: Locally advanced non-small-cell lung cancer; TCP: Tumor control probability; LQRG: Linear-quadratic model incorporating cell repair, redistribution, reoxygenation, regrowth and Gompertzian tumor growth; LQ: Linear-quadratic; LRC: Loco-regional control; OS: Overall survival; BED: Biologically effective dose; OTT: Overall treatment time; IGRT: Image guided radiotherapy; (SIB)-IMRT: Simultaneous integrated boost intensity-modulated radiotherapy; SCLC: Small cell lung cancer; SBRT: Stereotactic body radiation therapy; GTV: Gross tumor volume; CTV: Clinical target volume; PTV: Planning target volume; CT: Computed tomography; PET: Positron emission tomography; MRI: Magnetic resonance imaging;
SF: Surviving fraction; DVH: Dose-volume histograms; AIC: Akaike information criterion; CCRT: Concurrent chemoradiotherapy

Acknowledgements
Not applicable.

Authors’ contributions
All authors should have made substantial contributions to all of the following: (1) HL, YZ contributed to the conception and design of the study. (2) BQ, QWL, XLA, JZ, LC and JYG contributed to acquisition of data. (3) BQ, QWL, BW, JH, ZFZ, QHY, MJ, HHI and CL. Analyzed and interpreted data. (4) BQ, QWL, XLA drafted the article. (5) HL and YZ made the final approval of the version to be submitted. All authors read and approved the final manuscript.

Funding
This work was supported by Science and Technology Planning Project of Guangdong Province, China [Grant Number 2016A020215190, 2016ZC0030], the National Key R&D Program of China [Grant Number 2018YFC0116800], Suzhou Municipal Science and Technology Program [Grant Number SY20180009], Suzhou New and High-Tech Zone Healthcare Program [Grant Number 20172001] and Huzhou Healthcare Program [Grant Number 2018GY09].

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The treatment of all patients was discussed by the thoracic multi-disciplinary committee of Sun Yat-sen University Cancer Center. Written informed consent for publication from the corresponding author on reasonable request.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing financial interests.

Author details
1Department of Radiation Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, P. R. China. 2State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, P. R. China. 3Department of Radiation Oncology, The Affiliated Suzhou Science&Technology Town Hospital of Nanjing Medical University, Suzhou, Jiangsu, P. R. China. 4Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P. R. China. 5Department of Radiation Oncology, Zhebei Mingzhou Hospital, Huzhou, Zhejiang, P. R. China. 6Evidence Medical Technologies Inc., Suzhou, Jiangsu, P. R. China. 7Homology Medical Technologies Inc., Suzhou, Jiangsu, P. R. China.

Received: 3 December 2019 Accepted: 27 April 2020
Published online: 27 May 2020

References
1. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Foumel P, et al. Meta-analysis of concomitant versus sequential radiotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–90.
2. Machtay M, Paulus R, Rougjan H, Komaki R, Bradley JE, Choy H, et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol. 2012;7:216–22.
3. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IB or IIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–99.
4. Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76:775–81.
5. Li Q-W, Qiu B, Wang B, Zhang J, Chen L, Zhou Y, et al. Comparison of hyper- and hypofractionated radiotherapy schemes with IMRT technique in small cell lung cancer: clinical outcomes and the introduction of extended LQ and TCP models. Radiat Oncol. 2019;14:98–105.
6. Mehta N, King CR, Agazaryan N, Steinberg M, Hua A, Lee P. Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: a pooled analysis of biological equivalent dose and local control. Pract Radiat Oncol. 2012;2:288–95.
7. Tai A, Liu F, Gore E, Li YA. An analysis of tumor control probability of stereotactic body radiation therapy for lung cancer with a regrowth model. Phys Med Biol. 2016;61:3903–13.
8. Liu F, Tai A, Lee P, Biswas T, Ding QX, El Naga I, et al. Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models. Radiother Oncol. 2017;122:286–94.
9. Ma L, Qiu B, Li Q, Chen L, Wang B, Hu Y, et al. An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy. Radiat Oncol. 2018;13:130.
10. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679–94.
11. Lea DE. Actions of radiations on living cells. London: Cambridge University Press; 1946.
12. Sachs RK, Hlatky LR, Hahnfeldt P. Simple ODE models of tumour growth and anti-angiogenic or radiation treatment. Mathl Comput Model. 2001;33:1297–305.
13. Brenner DJ, Hlatky LR, Hahnfeldt PJ, Hall EJ, Sachs RK. A convenient extension of the linear-quadratic model to include redistribution and reoxygenation. Int J Radiat Oncol Biol Phys. 1995;32:379–90.
14. Speer JF, Petsosky VE, Retzky MW, Wardwell RH. A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res. 1994;44:4124–30.
15. Thames HD Jr, Peters LJ, Withers HR, Fletcher GH. Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys. 1983;9:127–38.
16. Moraru IC, Tai A, Erickson B, Li YA. Radiation dose responses for chemoradiation therapy of pancreatic cancer: an analysis of compiled clinical data using biophysical models. Pract Radiat Oncol. 2014;4:13–9.
17. Bates DM, Watts DG. Nonlinear regression analysis and its applications; 1988.
18. Mauguen A, Le Pechoux C, Saunders MI, Smith SE, Turnis AT, Baumann M, et al. Hyperfractionated or accelerated radiotherapy in lung cancer; an individual patient data meta-analysis. J Clin Oncol. 2012;30:2788–97.
19. Kastner TS, Varekamp B, Palma DA, Rodrigues GB. Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature. Clin Lung Cancer. 2015;16:71–9.
20. Kong FM, Ten Haken RK, Schipper M, Frey KA, Hayman J, Gross M, et al. Effect of Midtreatment PET/CT-adapted radiotherapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: a phase 2 clinical trial. JAMA Oncol. 2017;3:1358–65.
21. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131–46.
22. Machtay M, Bae K, Movas B, Paulus R, Gore EM, Komaki R, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small-cell lung carcinoma treated with chemoradiation: an analysis of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 2012;82:2425–34.
23. Fowler JF, Chappell R. Non-small-cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys. 2000;46:516–7.
24. Steel GG. Basic clinical radiobiology, 3rd edn. London: Arnold; 2002.
25. Fowler JF. Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol. 2001;40:712–7.
26. Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, et al. Impact of intensity-modulated radiotherapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35:556–62.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.